Drug resistance in metastatic castration-resistant prostate cancer

Nature Reviews Clinical Oncology

Volumn 8, Issue 1, 2011, Pages 12-23

  Seruga, Bostjan ^a   Ocana, Alberto ^a   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CIXUTUMUMAB; CUSTIRSEN; DASATINIB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FIGITUMUMAB; GEFITINIB; ISPINESIB; LAPATINIB; MEMBRANE RECEPTOR; MITOXANTRONE; MONOCLONAL ANTIBODY; NILUTAMIDE; OBLIMERSEN; PERTUZUMAB; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SAMARIUM 153; SILTUXIMAB; TAXANE DERIVATIVE; TH 302; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANDROGEN SYNTHESIS; AR GENE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CELL PROLIFERATION; CELL SUBPOPULATION; CELL SURVIVAL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; GENE; HUMAN; METASTASIS POTENTIAL; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN STRUCTURE; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR VASCULARIZATION;

EID: 85028107326     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.136     Document Type: Review

References (92)

1. Tredan, O., Galmarini, C. M., Patel, K. & Tannock, I. F. Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst. 99, 1441-1454 (2007).
2. Knight, Z. A., Lin, H. & Shokat, K. M. Targeting the cancer kinome through polypharmacology Nat. Rev. Cancer 10, 130-137 (2010).
3. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355, 1491-1498 (2000).
4. Eisenberger, M. A. & walsh, P. C. Early androgen deprivation for prostate cancer? N. Engl. J. Med.341, 1837-1838 (1999).
5. Berthold, D. R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26, 242-245 (2008).
6. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004). (Pubitemid 39315317)
7. Berthold, D. R., Pond, G. R., de wit, R., Eisenberger, M. & Tannock, I. F. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann. Oncol. 19, 1749-1753 (2008).
8. Craft, N., Shostak, Y., Carey, M. & Sawyers, C. L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5, 280-285 (1999). (Pubitemid 29124362)
9. Zhu, M. L. & Kyprianou, N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr. Relat. Cancer 15, 841-849 (2008).
10. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
11. Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45 (2001). (Pubitemid 33741879)
12. Gelmann, E. P. Molecular biology of the androgen receptor. J. Clin. Oncol. 20, 3001-3015 (2002).
13. Holzbeierlein, J. et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164, 217-227 (2004). (Pubitemid 38364606)
14. Shah, R. B. et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 64, 9209-9216 (2004).
15. Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39, 41-51 (2007).
16. Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med.10, 33-39 (2004).
17. Tamura, K. et al. Molecular features of hormonerefractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 67, 5117-5125 (2007). (Pubitemid 46997247)
18. Koivisto, P. et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57, 314-319 (1997). (Pubitemid 27036612)
19. Stanbrough, M. et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66, 2815-2825 (2006).
20. Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447-4454 (2008).
21. Gregory, C. w., Johnson, R. T. Jr, Mohler, J. L., French, F. S. & wilson, E. M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61, 2892-2898 (2001). (Pubitemid 32691931)
22. Brooke, G. N. & Bevan, C. L. The role of androgen receptor mutations in prostate cancer progression. Curr. Genomics 10, 18-25 (2009).
23. Tremblay, A., Tremblay, G. B., Labrie, F. & Giguere, V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol. Cell. 3, 513-519 (1999). (Pubitemid 29292608)
24. Xu, J., wu, R. C. & O'Malley, B. w. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat. Rev. Cancer 9, 615-630 (2009).
25. wang, G., wang, J. & Sadar, M. D. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res. 68, 9918-9927 (2008).
26. wu, L., Birle, D. C. & Tannock, I. F. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 65, 2825-2831 (2005). (Pubitemid 40490085)
27. Boldt, S., weidle, U. H. & Kolch, w. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23, 1831-1838 (2002). (Pubitemid 35355933)
28. Zelivianski, S. et al. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int. J. Cancer 107, 478-485 (2003). (Pubitemid 37266470)
29. Domingo-Domenech, J. et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin. Cancer Res. 12, 5578-5586 (2006). (Pubitemid 44497276)
30. Mimeault, M. et al. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol. Cancer Ther. 6, 967-678 (2007). (Pubitemid 46554566)
31. Banerjee, S. et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 67, 3818-3826 (2007). (Pubitemid 46762169)
32. Lo Nigro, C. et al. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU Int.102, 622-627 (2008).
33. Raffo, A. J. et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55, 4438-4445 (1995).
34. Zhang, M., Latham, D. E., Delaney, M. A. & Chakravarti, A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24, 2474-2482 (2005). (Pubitemid 40593038)
35. Yang, C. C. et al. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J. Biol. Chem. 278, 25872-25878 (2003).
36. Zoubeidi, A., Chi, K. & Gleave, M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin. Cancer Res.16, 1088-1093 (2010).
37. Yamanaka, K. et al. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int. 97, 1300-1308 (2006). (Pubitemid 43907340)
38. Pchejetski, D. et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol. Cancer Ther.7, 1836-1845 (2008).
39. Mumenthaler, S. M. et al. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol. Cancer Ther. 8, 2882-2893 (2009).
40. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22 (2010).
41. Brown, J. M. & wilson, w. R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447 (2004).
42. Primeau, A. J., Rendon, A., Hedley, D., Lilge, L. & Tannock, I. F. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res. 11, 8782-8788 (2005). (Pubitemid 43005929)
43. Kyle, A. H., Huxham, L. A., Yeoman, D. M. & Minchinton, A. I. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin. Cancer Res. 13, 2804-2810 (2007).
44. Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806-813 (2004). (Pubitemid 39331152)
45. Semenza, G. L. Defining the role of hypoxiainducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634 (2010).
46. Kasper, S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev. 4, 193-201 (2008).
47. Maitland, N. J. & Collins, A. T. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 26, 2862-2870 (2008).
48. Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
49. Komiya, A. et al. Neuroendocrine differentiation in the progression of prostate cancer. Int. J. Urol.16, 37-44 (2009).
50. Meads, M. B., Gatenby, R. A. & Dalton, w. S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9, 665-674 (2009).
51. Kobayashi, H. et al. Acquired multicellularmediated resistance to alkylating agents in cancer. Proc. Natl Acad. Sci. USA 90, 3294-3298 (1993). (Pubitemid 23111352)
52. Logothetis, C. J., Navone, N. M. & Lin, S. H. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin. Cancer Res. 14, 1599-1602 (2008). (Pubitemid 351469442)
53. Logothetis, C. J. & Lin, S. H. Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5, 21-28 (2005). (Pubitemid 40052322)
54. Zhang, J., Lu, Y. & Pienta, K. J. Multiple roles of chemokine (C-C Motif) ligand 2 in promoting prostate cancer growth. J. Natl Cancer Inst. 102, 522-528 (2010).
55. Qian, D. Z. et al. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 70, 433-442 (2010).
56. Fizazi, K. The role of Src in prostate cancer. Ann. Oncol. 18, 1765-1773 (2007). (Pubitemid 350119560)
57. Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10, 194-204 (2010).
58. Haldar, S., Basu, A. & Croce, C. M. Bcl2 is the guardian of microtubule integrity. Cancer Res. 57, 229-233 (1997). (Pubitemid 27038278)
59. Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATPdependent transporters. Nat. Rev. Cancer 2, 48-58 (2002). (Pubitemid 37328807)
60. Berrieman, H. K., Lind, M. J. & Cawkwell, L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol. 5, 158-164 (2004). (Pubitemid 38262847)
61. Seve, P. & Dumontet, C. Is class III beta-tubulin a predictive factor in patients receiving tubulinbinding agents? Lancet Oncol. 9, 168-175 (2008). (Pubitemid 351150128)
62. Verrills, N. M. et al. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. J. Natl Cancer Inst. 98, 1363-1374 (2006).
63. Bhalla, K. N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22, 9075-9086 (2003).
64. Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571 (2008).
65. Ryan, C. et al. Phase II multicenter study of chemotherapy (chemo)-naive castrationresistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone [abstract]. J. Clin. Oncol. 27 (Suppl.), a5046 (2009).
66. Danila, D. C. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castrationresistant prostate cancer. J. Clin. Oncol. 28, 1496-1501 (2010).
67. Tran, C. et al. Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790 (2009).
68. Scher, H. I. et al. Phase I-II study of MDV3100 in castration-resistant prostate cancer (CRPC) [abstract]. J. Clin. Oncol. 27, a151 (2009).
69. Attard, G., Cooper, C. S. & de Bono, J. S. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16, 458-462 (2009).
70. Mendiratta, P. et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J. Clin. Oncol. 27, 2022-2029 (2009).
71. whang, J. E. et al. A phase II trial of lapatinib in hormone refractory prostate cancer [abstract]. J. Clin. Oncol. 26 (15S), a16037 (2008).
72. Gross, M. et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 7, 142 (2007). (Pubitemid 47244883)
73. Gravis, G. et al. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann. Oncol. 19, 1624-1628 (2008).
74. Canil, C. M. et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. 23, 455-460 (2005). (Pubitemid 46224221)
75. de Bono, J. S. et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J. Clin. Oncol. 25, 257-262 (2007).
76. De Bono, J. S. et al. Randomized phase II study of CNTO 328 (C), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone (M) versus M alone in metastatic castrationresistant prostate cancer (CRPC) [abstract]. Genitourinary Cancer Symposium a86 (2010).
77. Sternberg, C. N. et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann. Oncol.20, 1264-1269 (2009).
78. Saad, F. et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer who relapsed on or within six months of 1st-line docetaxel therapy [abstract]. J. Clin. Oncol. 26, a5002 (2008).
79. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
80. Ning, Y. M. et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 2070-2076 (2010).
81. Dahut, w. L. et al. Randomized phase II trial of docetaxel plus thalidomide in androgenindependent prostate cancer. J. Clin. Oncol. 22, 2532-2539 (2004). (Pubitemid 41103740)
82. Sonpavde, G. et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol. 21, 319-324 (2010).
83. Kelly, w. K. et al. A randomized double-blind placebo controlled phase III trial comparing docetaxel, prednisone and placebo with docetaxel, prednisone and bevacizumab in men with metastatic castration-resistant prostate cancer: survival results of CALGB 90401 [abstract]. J. Clin. Oncol. 28 (Suppl.), a4511 (2010).
84. Carducci, M. A. et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormonerefractory prostate cancer. Cancer 110, 1959-1966 (2007).
85. Tu, S. M. et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357, 336-341 (2001).
86. Fizazi, K. et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J. Clin. Oncol. 27, 2429-2435 (2009).
87. Nisson, S. et al. A randomized, placebocontrolled, phase 2 study of radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC). Twelve months follow-up data [abstract]. Prostate Cancer Symposium a259, (2007).
88. Machiels, J. P. et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 26, 5261-5268 (2008).
89. Garmey, E. G., Sartor, O., Halabi, S. & Vogelzang, N. J. Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin. Adv. Hematol. Oncol. 6, 118-122, 127-132 (2008). (Pubitemid 351484770)
90. Sternberg, C. N. et al. Multinational, doubleblind, phase III study of prednisone and either satraplatin or placebo in patients with castraterefractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J. Clin. Oncol. 27, 5431-5438 (2009).
91. Sartor, A. O. et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC) [abstract]. Genitourinary Cancer Symposium a9 (2010).
92. Lee, J. J. & Kelly, w. K. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Nat. Clin. Pract. Oncol. 6, 85-92 (2009).